SUMITOMO PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 387 JPY | -1.28% |
|
-4.91% | -16.95% |
| Apr. 02 | Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise | MT |
| Apr. 02 | Roivant's anti-inflammatory drug succeeds in mid-stage study | RE |
| Sales 2024 * | 328B 2.13B | Sales 2025 * | 360B 2.33B | Capitalization | 156B 1.01B |
|---|---|---|---|---|---|
| Net income 2024 * | -164B -1.06B | Net income 2025 * | -43.57B -282M | EV / Sales 2024 * | 1.36 x |
| Net Debt 2024 * | 292B 1.89B | Net Debt 2025 * | 303B 1.96B | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-3.71
x | Employees | 6,250 |
| Yield 2024 * |
-
| Yield 2025 * |
0.98% | Free-Float | 42.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sumitomo Pharma Co., Ltd.
More recommendations
More press releases
| 1 day | -3.69% | ||
| 1 week | -3.92% | ||
| Current month | -1.51% | ||
| 3 months | -21.13% | ||
| 6 months | -17.02% | ||
| Current year | -15.88% |
1 week
392.00
414.00
1 month
380.00426.00
Current year
324.00505.00
1 year
324.00865.00
3 years
324.002 363.00
5 years
324.002 534.00
10 years
324.004 135.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hiroshi Nomura
CEO | Chief Executive Officer | 66 | 05-09-30 |
Masayo Tada
CHM | Chairman | 79 | 05-09-30 |
Yoshiharu Ikeda
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Saeko Arai
BRD | Director/Board Member | 60 | 18-05-31 |
Nobuhiro Endo
BRD | Director/Board Member | 70 | 19-05-31 |
Masayo Tada
CHM | Chairman | 79 | 05-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 15 M€ | +5.02% | ||
| 0.15% | 67,864 M€ | +18.09% | ||
| 0.13% | 31,732 M€ | +18.19% | - | |
| 0.13% | 1,198 M€ | +17.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 387 | -1.28% | 2 991 100 |
| 24-04-15 | 392 | -3.69% | 2,760,100 |
| 24-04-12 | 407 | +0.74% | 1,639,000 |
| 24-04-11 | 404 | +0.25% | 1,544,000 |
| 24-04-10 | 403 | -0.98% | 1,399,900 |
Delayed Quote Japan Exchange, April 15, 2024 at 02:00 am EDT
More quotes
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
407
JPY
Average target price
405
JPY
Spread / Average Target
-0.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.88% | 1.06B | |
| +31.16% | 677B | |
| +26.29% | 560B | |
| -4.86% | 355B | |
| +16.80% | 319B | |
| +5.03% | 287B | |
| +3.94% | 214B | |
| +1.91% | 207B | |
| -8.06% | 199B | |
| -9.41% | 146B |
- Stock Market
- Equities
- 4506 Stock
